Defendant Name: Mylan N.V.

Defendant Type: Public Company
SIC Code: 2834
CUSIP: N5946510

Initial Case Details

Legal Case Name SEC v. Mylan N.V.
First Document Date 27-Sep-2019
Initial Filing Format Civil Proceeding
Case Number 19-cv-02904
Allegation Type Issuer Reporting and Disclosure
Federal District Court District of Columbia, District of Columbia

Violations Alleged

Exchange Act
• Rule 12b-20
• Sec 13(a)
• Rule 13a-1
• Rule 13a-11
• Rule 13a-13
• Sec 13(b)(2)(A)
• Sec 13(b)(2)(B)
Securities Act
• Sec 17(a)(2)
• Sec 17(a)(3)

Resolutions

First Resolution Date 27-Sep-2019
Headline Total Penalty and Disgorgement $30,000,000

Related Documents:

LR-24621 27-Sep-2019 Litigation Release
Mylan to Pay $30 Million for Disclosure and Accounting Failures Relating to Epipen
The Commission stated: "The Securities and Exchange Commission today announced charges against Pennsylvania-based pharmaceutical company Mylan N.V. for accounting and disclosure failures relating to a Department of Justice probe into whether Mylan overcharged Medicaid by hundreds of millions of dollars for EpiPen, its largest revenue and profit generating product. Mylan agreed to pay $30 million to settle the SEC's charges."
comp-pr2019-194 27-Sep-2019 Complaint
Complaint
The Commission stated: "Mylan N.V. ("Mylan") failed to timely disclose to investors a possible loss relating to a nearly two-year Department of Justice ("DOJ") probe into whether Mylan overcharged Medicaid by hundreds of millions of dollars for sales of EpiPen Auto-Injector ("EpiPen") by misclassifying EpiPen as a "generic" or "non-innovator" drug."
2019-194 27-Sep-2019 Press Release--Civil Action
Mylan to Pay $30 Million for Disclosure and Accounting Failure Relating to EpiPen
The Commission stated: "The Securities and Exchange Commission today announced charges against Pennsylvania-based pharmaceutical company Mylan N.V. for accounting and disclosure failures relating to a Department of Justice (DOJ) probe into whether Mylan overcharged Medicaid by hundreds of millions of dollars for EpiPen, its largest revenue and profit generating product. Mylan agreed to pay $30 million to settle the SEC's charges."
court_doc5_19-cv-02904 01-Oct-2019 Court Docket Document
Final Judgment as to Defendant Mylan N.V.
The Court stated: "The Securities and Exchange Commission having filed a Complaint and Defendant, Mylan N.V. having entered a general appearance; consented to the Court's jurisdiction over Defendant and the subject matter of this action; consented to entry of this Final Judgment without admitting or denying the allegations of the Complaint (except as to jurisdiction); waived findings of fact and conclusions of law; and waived any right to appeal from this Final Judgment"